Blue Jet Healthcare Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/f787hnz7tisqnctdja29vgbw.pdf

Key Takeaways


Contrast Media: The Near-Term Drag and the Structural Buffer

Shiven Arora: "We have supplied this material for validation in the month of January. And today we have got a full approval from them. So, nothing could go wrong when it comes to the product quality. I think it has been established well. And the use test trials have come out fairly positive. So scale up will happen during this particular financial year."

The Cardiovascular Blockbuster Bet

VK Singh: "It's very difficult to predict how a molecule will behave, but all that we can say is that the data was presented to the FDA and the data was also presented to the American Cardiology College and both institutes which are institutes of international repute there is very high acceptability of this data because of the acceptability of this data the molecule is now indicated not only for secondary use, but as a primary treatment product... there is today no other oral product which can act as an adjunct to the statins. So, there is great potential. And we reckon that this would be a blockbuster."

Margins: An Accounting Aberration Masks Intact Gross Profitability

Ganesh Karuppannan: "This has nothing to do with our actual gross margin. That is intact. But this aberration has occurred only because our finished goods stock end of the year is lower than the previous quarter."

Capex and Capacity: Building for an Inflection


PI-API and the Broader Pipeline: Fructifying Incubation


Guidance & Commitments

CommitmentSpecificsTimeline
Contrast media volume recoveryVolumes return to historical levels after customer shutdown impact subsidesFrom Q3 FY25 onwards
Contrast media normalizationNormalization of supply to the largest customerQ2 FY25
Iodinated advanced intermediate scale-upScale-up of newly approved intermediateDuring FY25
Unit 2 Ambernath validationBlock ready for validation batchesQ1 FY25
Unit 2 commercialization and supply uptickLarger capacity on-stream, supplies increaseQ2 FY25
Unit 3 Mahad validationPlant ready for validation batches (one-quarter delay)Q1 FY26
Unit 3 multipurpose block validationBlock validatedQ2 FY26
Unit 4 Greenfield on-streamSite operationalH2 FY27
Annual capex floorAt least ₹200 crores per annumFY25 and FY26
PI-API launchesA couple of product launchesFY25
Employee cost increaseSignificantly higher employee cost from senior hires and R&D expansionFY25
Gross margin mix shiftGross margins may go down by a percent or two with higher PI-API growthFY25

Key Metrics

MetricQ4 FY24
Revenue from operations (FY24)₹708 cr, degrowth of 1.3% vs ₹718 cr in FY23
Q4 sales growth (QoQ)10% growth compared to Q3
EBITDA (FY24, before extraordinary item)32.2%, improvement of 1.8% vs FY23
EBITDA (Q4)Dropped approximately 3.9% vs Q3, due to change in WIP and finished goods of ~₹27.4 cr
PAT (Q4)21.6%, improvement of 2.3% vs Q3
PAT (FY24)23%, compared to 22.2% in FY23
Extraordinary expense (Mahad incident)₹9.7 cr, classified as extraordinary item in FY24
Contrast media revenue share (FY24)~68% of revenues
Pharma intermediates (CRAM) revenue share (FY24)~14% of business, grew ~156% year-on-year
ROCE26%
Fixed asset turnoverNorth of 5x
Capex spent (FY24)Close to ₹200 cr, capitalized plus capital work in progress
Capex guidance (FY25 and FY26)At least ₹200 cr per annum for the next two years
Capex outlay (three-year total)₹600 cr, increased from earlier estimate of ~₹500 cr
Renewable energy share60% to 70% of power requirement met from renewable sources
RFPs (pipeline indicator)2x of what they used to have